Sherlock Biosciences
Sherlock Biosciences raises $220M Series C at $1.5B valuation
Quick Facts
Sherlock Biosciences: Series C Funding Round
Sherlock Biosciences has successfully raised $220M in Series C funding, reaching a valuation of $1.5B.
Company Overview
CRISPR-powered diagnostics
Funding Details
The Series C round was led by Vivo Capital, with participation from Baillie Gifford, GV, Taiho Ventures, Perceptive Advisors, William K. Warren Foundation.
Company Information
- Headquarters: 201 Brookline Avenue, Boston, MA 02215
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Sherlock Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Vivo Capital: Verified investor in Series C
- Baillie Gifford: Verified investor in Series C
- GV: Verified investor in Series C
- Taiho Ventures: Verified investor in Series C
- Perceptive Advisors: Verified investor in Series C
- William K. Warren Foundation: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...